With the ongoing development of a global sales network in recent years, Haier Biomedical has received wide recognition from customers, especially in the US market and was highly favored as the preferred provider of life science and biomedical solutions.

Kyverna Therapeutics is one of Haier Biomedical’s important customers in the US. In the first half of the year, they closed $85 million series B financing. Proceeds from the financing will be used to advance the phase 2 clinical trials of KYV-101, CAR-T cell therapy for autoimmune diseases initiated in the first half of the year, and to support the continued development of the engineered T cell therapy. “I admired Haier Biomedical’s corporate culture very much, and Haier Biomedical’s product provided Kyverna Therapeutics with a strong product portfolio.” said Stefanie, the Facility Director of Kyverna Therapeutics.

Different with Kyverna Therapeutics, Geltor is an American bio-design company that focuses on designing and producing high-performance protein products, but that doesn’t stop the team from loving Haier Biomedical’s energy-saving ultra-low temperature freezers. Continue Reading >>